iShares US Medical Devices

Mizuho lowers Abbott's target price to $115 from $125

Fisher Funds Management LTD Reduced Holdings in Edwards Lifesciences

Jefferies Downgrades Abbott's Target Price

Abbott Reports Q1 Earnings in Line with Estimates, Q2 Forecast Below Consensus

Abbott Exceeds Q1 Earnings Estimates, Announces $23B Precision Biosciences Acquisition

Stryker Updates Mandibular Joint Implant Instructions

FactSet Analysts Lower Medtronic's 2026 EPS Forecast to $5.52

Truist Financial cuts Intuitive Surgical target price to $580

RBC Capital Analyst Maintains Buy Rating on Edwards Lifesciences

Boston Scientific to Release FY2026 Q1 Earnings on April 22 Pre-Market EST, Forecast Revenue USD 5.18 B, EPS USD 0.555

Two Experts Propose Strategic Tariff Policy for U.S. Medical Equipment Industry

Becton Dickinson Reports Record Revenue for Fiscal 2025

Third View Private Wealth LLC Invests in IDEXX Laboratories As Insiders Sell Heavily

Abbott Expected To Report Q1 Earnings On April 16

Intuitive Surgical to Release FY2026 Q1 Earnings on April 21 During-Market EST, Forecast Revenue USD 2.618 B, EPS USD 1.9583

Medtronic Integrates GE Healthcare's System to Enhance Neurosurgery Capabilities

FactSet reduces Boston Scientific target price forecast

Stryker Signs Final Agreement to Acquire Amplitude Vascular Systems

Ryan Zimmerman Maintains Buy Rating on GE Healthcare Technologies Inc

BTIG Analyst Maintains Buy Rating on Intuitive Surgical

Myseum

Onfolio

Psyence Biomedical

Meiwu Tech

WeShop

Julong

Mega Fortune

Dare Bioscience

Greenland Energy

Tradr 2X Long NVTS Daily ETF

Pinned News

置顶新闻

Fisher Funds Management LTD Decreases Position in Edwards Lifesciences Corporation $EW

Fisher Funds Management LTD reduced its stake in Edwards Lifesciences Corporation (NYSE:EW) by 14.2% in Q4, now holding 761,899 shares after selling 125,697 shares. This represents about 1.7% of their portfolio, valued at $65.15 million. Other investors have also adjusted their positions, with significant increases and new purchases noted. Analysts maintain a consensus rating of "Moderate Buy" for Edwards Lifesciences, with a price target averaging $95.74. Recent insider sales have also been reported, indicating active trading among executives.

Market Beat

Edwards Lifesciences

SPDR S&P Health Equip

Rakuten Group, Inc.

Lotte Group

AstraZeneca

AstraZeneca PLC

Zimmer Biomet

Goldman Sachs

Mizuho Financial Group, Inc.

Mizuho Financial

UBS Group AG

Piper Sandler Cos

GS Hldg R

AIMD

Ainos is expanding its Smell AI technology into hospital infrastructure through a partnership with MacKay Memorial Hospital and Topco Scientific. The initial focus is on environmental monitoring and safety in power systems, HVAC, and clinical laboratories. Ainos aims to transition from pilot projects to scalable deployments by 2026, enhancing its revenue potential. This expansion marks a shift from semiconductor and industrial applications to healthcare, while also developing Smell ID data and a Smell Language Model for improved data utilization.

PUBT

Ainos

ACCESS Newswire

AINOS INC C/WTS 29/07/2027 (TO PUR COM)

Ainos expands Smell AI deployments into hospital infrastructure with MacKay Memorial Hospital

ARKG

Volastra Therapeutics has announced significant findings related to KIF18A inhibitors ahead of the AACR 2026 Annual Meeting. The company identified p16 loss as a predictive biomarker for KIF18A inhibition, supporting its development across various tumor types. The data suggest a pan-cancer strategy based on Rb pathway biology, with promising results from a study involving heavily pretreated ovarian cancer patients. Additionally, preclinical data show synergy between KIF18A inhibitors and taxanes, indicating potential for earlier line therapies. Volastra aims to leverage these insights for clinical development and patient selection.

MorningStar

iShares Global Healthcare

Proshares UltraShort Nasdaq Biotech

SPDR S&P Biotech

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Guotai CSI Bio-medicine ETF

Hwabao WP CSI Medical Service ETF

China Merchants CSI Biotechnology Theme ETF

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

iShares US Pharma

VanEck Biotech ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Volastra Therapeutics Announces Biomarker and Combination Data around AACR 2026 Defining an Rb Pathway-Driven Pan-Cancer Development Strategy for KIF18A Inhibitors

159883

159898

Reuters

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

ChinaAMC CSI All Share Health Care Devices ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

First Trust NYSE Arca Biotech Index Fd

VG Health

ALPS Medical Breakthrough

TP ICAP Group plc

Jefferies Financial

BUZZ-Virbac shares rise on strong Q1 revenue growth

Koninklijke Philips Elect

Koninklijke Philips N.V.

Philips Receives FDA 510(K) Clearance For Verida

EXAS

Abbott Laboratories held its Q1 earnings call, highlighting steady growth and strong device momentum despite near-term pressures. Adjusted EPS reached $1.15, with Q2 guidance of $1.25–$1.31. The Exact Sciences acquisition is expected to add $3 billion in sales, while medical devices showed 8.5% growth. Continuous glucose monitoring generated $2 billion in revenue. However, rapid diagnostics faced a 10% decline due to weak respiratory testing. Overall, Abbott maintains a 6.5%–7.5% sales growth outlook for 2026, despite challenges in China and EPS dilution from acquisitions.

Tip Ranks

Abbott Laboratories

Exact Sciences

Abbott Laboratories Bets on Devices in 2026 Call

Abbott Laboratories (NYSE:ABT) reported Q1 earnings of $1.15 per share, beating estimates, but cut its 2026 earnings outlook, leading to a 4.76% drop in stock price to $96.72, a new 52-week low. Despite a 7.8% increase in quarterly sales to $11.16 billion, the company anticipates adjusted earnings for 2026 to be $5.38-$5.58 per share, below Wall Street's $5.62 consensus. Medical devices and diabetes care drove growth, while diagnostics and nutrition sales declined due to weaker demand and strategic pricing actions.

benzinga_article

AST SpaceMobile

Amazon

Globalstar

Shutterstock

Abbott Labs Annual Guidance Cut Overshadows Earnings Beat, Stock Cracks

HLTHQ

CTKB

A prominent gastrointestinal molecular diagnostics company, Cyted Health, has revealed on April 16, 2026, that they are currently conducting a clinical validation study at various locations in the United States. The company, headquartered in WILMINGTON, Del., and CAMBRIDGE, England, shared that their laboratory in the US has successfully accomplished this milestone. The study spans across multiple sites and is aimed at validating their technology and methods. This news signifies a significant step for Cyted Health as they work towards further establishing their presence in the field.

Unusual Whales

CUE HEALTH INC

Cytek Biosciences

Cyted Health's US Laboratory Achieves College of American Pathologists Accreditation

Danaher Corporation (NYSE:DHR) experienced a 25.0% increase in short interest in March, totaling 6,939,368 shares as of March 31. The short-interest ratio is currently 1.6 days, with approximately 1.1% of shares short sold. The company's stock traded down to $194.25, with a market cap of $137.47 billion. Danaher recently announced a quarterly dividend of $0.40 per share, up from $0.32, with a dividend yield of 0.8%. Institutional investors own 79.05% of the company's stock, reflecting strong interest in the firm.

Danaher

Direxion S&P Biotech Bear 3X

Johnson Controls

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Danaher Corporation (NYSE:DHR) Short Interest Up 25.0% in March

Stryker

US FDA Stryker Updates Use Instructions For Patient-Fitted Tmj Implants

Rapid Medical™ has received FDA clearance for its TIGERTRIEVER™ 25, the largest clot retrieval device designed for large vessel occlusion (LVO) stroke treatment. This device features a 53 mm capture length and real-time force control, allowing physicians to manage clot interaction effectively. Initial clinical cases demonstrate its adaptability and performance in challenging anatomical scenarios, aiming for first-pass success in thrombectomy procedures. The TIGERTRIEVER™ 25 enhances Rapid Medical's offerings in neurovascular treatment, complementing previous validations in smaller vessels.

Rapid Medical™ Announces FDA Clearance of TIGERTRIEVER™ 25 and First Clinical Cases

NIVF

FertilAI has received the world's first CE marking for its AI-driven clinical decision support tools under the EU Medical Device Regulation. The approval includes two algorithms, StimAI and OvuPredict, which enhance fertility treatment by predicting optimal timing for procedures and improving clinical precision. This technology aims to streamline clinic operations and increase patient access to fertility services, addressing the global rise in infertility and physician shortages. FertilAI's solutions are integrated with existing electronic medical record systems, supporting individualized patient care and efficient workload management.

prnewswire

INVO Fertility

NewGenIvf

SPDR S&P Health

iShares Genomics Immunology and Healthcare ETF

iShares US Healthcare Providers

15:51 ETFertilAI Secures World's First CE Mark for Predictive AI in Fertility Treatment Cycle Optimization

London Stock Exchange Group plc

Abbott first-quarter results beat on cancer diagnostics, medical device strength

Abbott Laboratories reported an adjusted earnings per share of $1.15 for the first quarter, exceeding Wall Street's expectation of $1.14. Comparable sales grew by 3.7%, reaching $11.16 billion. The medical devices business performed strongly, with revenue of $5.5 billion, but the nutrition business remained weak, with comparable sales declining by 7.7%. The company updated its full-year guidance, expecting adjusted earnings per share to be between $5.38 and $5.58, while maintaining a same-store sales growth expectation of 6.5% to 7.5%

AASTOCKS

"Performance" Abbott's quarterly results exceed expectations, but the nutrition business remains weak

Myomo

Myomo Appoints William J Febbo To Its Board Of Directors

NURO

STIM

5999

Science Corporation announced that it will launch human trials for its biological hybrid brain-computer interface (BCI) and has appointed Dr. Murat Gunel, the Director of Neurosurgery at Yale University, as a scientific advisor. Unlike Neuralink's invasive approach, the company uses biological hybrid technology to integrate lab-grown neurons with the human brain. Initial trials are planned to start in 2027, focusing on safety and signal acquisition capabilities for stroke patients. The company has completed a $230 million Series C financing round, reaching a valuation of $1.5 billion, and plans to list its PRIMA vision restoration device in Europe

PingWest

NeuroMetrix

Neuronetics

Ihara Science Corporation

Science Corporation plans to initiate human trials for its biological hybrid brain-machine interface

iShares US Medical Devices(IHI.US)

iShares US Medical Devices Stock Performance Chart

Fisher Funds Management LTD Decreases Position in Edwards Lifesciences Corporation $EW

Ainos expands Smell AI deployments into hospital infrastructure with MacKay Memorial Hospital

Volastra Therapeutics Announces Biomarker and Combination Data around AACR 2026 Defining an Rb Pathway-Driven Pan-Cancer Development Strategy for KIF18A Inhibitors

BUZZ-Virbac shares rise on strong Q1 revenue growth

Philips Receives FDA 510(K) Clearance For Verida